Listed by the USPTO as FRONDA, CHRISTIAN L
Tech Center 1600 • Art Units: 1645 1651 1652 1656
This examiner grants 82% of resolved cases
Christian L Fronda is a USPTO patent examiner in tech center 1600 and art unit 1645. The profile includes 1374 resolved cases, an allowance rate of 82.5%, and a median of 889 days to allowance. The interview lift is 14.2%, indicating a moderate recorded association between interviews and allowance outcomes.
Ketoneaid Inc., Novozymes A/S, and Alteogen Inc. are the listed companies. STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C., FOLEY & LARDNER LLP, and SUGHRUE MION, PLLC are the listed firms. The extensive record supports examiner-specific preparation, with timing relevant to portfolio planning.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18398165 | Nucleic Acid Synthesis and Sequencing Using Tethered Nucleoside Triphosphates | Final Rejection | The Regents of the University of California |
| 19051360 | MICROORGANISM HAVING INCREASED ACTIVITY OF 3-METHYL-2-OXOBUTANOATE HYDROXYMETHYLTRANSFERASE, AND USE THEREOF | Non-Final OA | CJ CheilJedang Corporation |
| 18739532 | DETERGENT COMPOSITIONS CONTAINING ENZYMES | Non-Final OA | The Procter & Gamble Company |
| 18319864 | ENGINEERED THERMOPHILIC REVERSE TRANSCRIPTASE | Final Rejection | 10x Genomics, Inc. |
| 18429717 | MITIGATION OF THERAPEUTIC PROTEIN FRAGMENTATION DURING CELL CULTURE HARVEST PROCESSES | Non-Final OA | AMGEN INC. |
| 19047328 | METHODS FOR PROCESSING NUCLEIC ACID SAMPLES | Non-Final OA | Bio-Rad Laboratories, Inc. |
| 19065553 | METHOD FOR THE FERMENTATIVE PRODUCTION OF L-LYSINE USING C. GLUTAMICUM STRAINS EXPRESSING A HETEROLOGOUS NICOTINAMIDE NUCLEOTIDE TRANSHYDROGENASE PNTAB AND HAVING AN INCREASED ACTIVITY OF A MYO-INOSITOL PERMEASE | Non-Final OA | Evonik Operations GmbH |
| 18847406 | ALPHA-AMYLASE VARIANT | Non-Final OA | KAO CORPORATION |
| 19023584 | METHODS TO MANIPULATE QUALITY ATTRIBUTES OF POLYPEPTIDES PRODUCED IN CHO CELLS | Non-Final OA | BRISTOL-MYERS SQUIBB COMPANY |
| 19019935 | PROCESSES FOR PRODUCING ETHANOL | Non-Final OA | NOVOZYMES A/S |
| 18956701 | POLYPEPTIDES HAVING LYSOZYME ACTIVITY, POLYNUCLEOTIDES ENCODING SAME AND USES AND COMPOSITIONS THEREOF | Final Rejection | Novozymes A/S |
| 18896095 | STABILIZED CELLULASE VARIANTS | Non-Final OA | Novozymes A/S |
| 18344244 | Food Composition Comprising L-Fucose | Final Rejection | Chr. Hansen A/S |
| 18246060 | METHOD FOR IMPROVING THE STABILITY OF A COMPOSITION COMPRISING A FLAVIN-DEPENDENT LACTATE DEHYDROGENASE | Final Rejection | KIKKOMAN CORPORATION |
| 18605800 | METHOD FOR PURIFYING TETANUS TOXIN OR VARIANTS THEREOF | Non-Final OA | SHANGHAI MICRODOM BIOTECH CO. LTD |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy82.5% of resolved applications examined by Christian L Fronda were allowed (1,374 resolved cases), compared with 49.4% across Art Unit 1645 over the last five years.
This examiner's interview lift is +14.2 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Christian L Fronda took 889 days on average from filing to allowance.
Christian L Fronda examines applications in Art Unit 1645 in Tech Center 1600 (Biotechnology & Pharmaceuticals).